Disease · MONDO_0006896
peptic esophagitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. peptic esophagitis. Diseases, record MONDO_0006896. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006896
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Esophagitis (& [reflux]) or esophageal reflux, Esophagitis, Peptic, Peptic reflux disease (disorder), Reflux esophagitis, Reflux oesophagitis
- Open Targets
Drugs15
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ESOMEPRAZOLE MAGNESIUM | CHEMBL5314366 | Small molecule | Approval | PMDA | 2 | 1 | 1 | Drugs and targets |
| VONOPRAZAN FUMARATE | CHEMBL2064032 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| ESOMEPRAZOLE | CHEMBL1201320 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 7 | Drugs and targets |
| RABEPRAZOLE | CHEMBL1219 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| LANSOPRAZOLE | CHEMBL480 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| OMEPRAZOLE | CHEMBL1503 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ABEPRAZAN | CHEMBL4594445 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ANAPRAZOLE | CHEMBL4651083 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FAMOTIDINE | CHEMBL902 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LAFUTIDINE | CHEMBL1742461 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 15
See all 15 drugsTargets3
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ATP4A | Potassium-transporting ATPase | 10 | Potassium-transporting ATPase inhibitor | Approval | https://conductscience.org/library/genes/495 | Drugs and targets |
| ATP4B | Potassium-transporting ATPase | 10 | Potassium-transporting ATPase inhibitor | Approval | https://conductscience.org/library/genes/496 | Drugs and targets |
| HRH2 | Histamine H2 receptor | 2 | Histamine H2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3274 | Drugs and targets |
Trials19
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03214952 | Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis" | 3,183 | 2019-12-12 | Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis | VONOPRAZAN | Its record names the disease | ClinicalTrials.gov | |
| NCT01669811 | Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus) | Phase 3 | 1,398 | 2015-08-14 | Refractory Reflux Esophagitis | ESOMEPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT03214081 | Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use" | 1,237 | 2019-10-23 | Reflux Esophagitis | VONOPRAZAN | Its record names the disease | ClinicalTrials.gov | |
| NCT00633932 | Reflux Esophagitis Phase III Study (Initial Treatment) | Phase 3 | 602 | 2010-04-08 | Reflux Esophagitis | ESOMEPRAZOLE, OMEPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT00634114 | Reflux Esophagitis Phase III Study (Maintenance Treatment) | Phase 3 | 540 | 2010-06-17 | Reflux Esophagitis | ESOMEPRAZOLE, OMEPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT02135107 | A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients | Phase 3 | 517 | 2018-11-19 | Gastroesophageal Reflux Disease | RABEPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT00770913 | Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis | Phase 2/3 | 337 | 2012-04-13 | Refractory Reflux Esophagitis | RABEPRAZOLE SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT01321567 | Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis | 2,157 | Refractory Reflux Esophagitis | RABEPRAZOLE | Its record names the disease | ClinicalTrials.gov | ||
| NCT00206284 | A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis. | Phase 2 | 1,400 | GERD Without Erosive Esophagitis | ESOMEPRAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT07010107 | A Clinical Trial of Anaprazole for Treating Reflux Esophagitis. | Phase 3 | 500 | Reflux Esophagitis (RE) | ANAPRAZOLE, RABEPRAZOLE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 19
See all 19 trialsComparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| D961H 20 mg BID vs D961H 20 mg QD + Placebo: serious adverse events | 1 of 145 | 3 of 142 | 287 | NCT01669811 |
Source Trial comparisons
Papers from its trials8
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006896
GET https://conductscience.org/api/diseases/v1/MONDO_0006896/drugs